Your session is about to expire
← Back to Search
Device
Tunneled Pleural Catheters for Refractory Effusions Attributed to Congestive Heart Failure (TREAT-CHF) Trial (TREAT-CHF Trial)
N/A
Waitlist Available
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year post-enrollment
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether a small tube inserted into the chest to drain lung fluid can help adults with heart failure who have ongoing fluid buildup around their lungs. These patients haven't improved with standard treatments. The goal is to see if this tube can make them feel better and reduce hospital visits.
Eligible Conditions
- Congestive Heart Failure
- Shortness of Breath
- Chronic Pleural Effusions
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year post-enrollment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year post-enrollment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in quality of life scores from baseline as measured by the Minnesota Living with Heart Failure Questionnaire
Incidence of hospitalizations and emergency room encounters
Secondary study objectives
All cause mortality
Change from baseline serum albumin
Change from baseline serum creatinine
+8 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention GroupExperimental Treatment1 Intervention
This group will receive placement of a tunneled pleural catheter to drain their recurrent, chronic, and symptomatic pleural effusion in addition to their usual medication therapy.
Group II: Usual CareActive Control1 Intervention
The control group will continue with medical therapy by their referring physician and serial thoracenteses when clinically appropriate.
Find a Location
Who is running the clinical trial?
University of California, Los AngelesLead Sponsor
1,567 Previous Clinical Trials
10,267,000 Total Patients Enrolled